Novo Nordisk A/S (NYSE:NVO) Stock Holdings Lowered by Paragon Private Wealth Management LLC

Paragon Private Wealth Management LLC lowered its position in shares of Novo Nordisk A/S (NYSE:NVO) by 13.1% in the 4th quarter, Holdings Channel reports. The fund owned 3,655 shares of the company’s stock after selling 552 shares during the period. Paragon Private Wealth Management LLC’s holdings in Novo Nordisk A/S were worth $314,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of the company. Marco Investment Management LLC grew its position in shares of Novo Nordisk A/S by 1.5% during the third quarter. Marco Investment Management LLC now owns 6,702 shares of the company’s stock worth $798,000 after acquiring an additional 100 shares during the last quarter. Menard Financial Group LLC lifted its holdings in Novo Nordisk A/S by 0.8% in the third quarter. Menard Financial Group LLC now owns 12,283 shares of the company’s stock worth $1,463,000 after purchasing an additional 102 shares during the period. Optimist Retirement Group LLC lifted its holdings in Novo Nordisk A/S by 4.3% in the third quarter. Optimist Retirement Group LLC now owns 2,747 shares of the company’s stock worth $327,000 after purchasing an additional 112 shares during the period. Financial Counselors Inc. lifted its holdings in Novo Nordisk A/S by 1.1% in the third quarter. Financial Counselors Inc. now owns 11,009 shares of the company’s stock worth $1,311,000 after purchasing an additional 115 shares during the period. Finally, M. Kulyk & Associates LLC lifted its holdings in Novo Nordisk A/S by 3.9% in the fourth quarter. M. Kulyk & Associates LLC now owns 3,182 shares of the company’s stock worth $274,000 after purchasing an additional 119 shares during the period. Institutional investors own 11.54% of the company’s stock.

Analyst Upgrades and Downgrades

NVO has been the subject of several research analyst reports. BMO Capital Markets reduced their price objective on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a report on Monday, December 23rd. Morgan Stanley initiated coverage on shares of Novo Nordisk A/S in a report on Wednesday, February 12th. They issued an “equal weight” rating for the company. Stifel Nicolaus downgraded shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Monday, March 3rd. BNP Paribas raised shares of Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, December 2nd. Finally, Sanford C. Bernstein raised shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. Three investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $145.25.

Novo Nordisk A/S Price Performance

NYSE NVO opened at $78.87 on Tuesday. The stock has a market capitalization of $353.91 billion, a P/E ratio of 23.97, a P/E/G ratio of 0.90 and a beta of 0.42. Novo Nordisk A/S has a 1 year low of $77.79 and a 1 year high of $148.15. The business’s fifty day moving average is $84.77 and its two-hundred day moving average is $104.45. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.74.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. On average, research analysts forecast that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The company also recently announced a semi-annual dividend, which will be paid on Tuesday, April 8th. Shareholders of record on Monday, March 31st will be paid a dividend of $0.7874 per share. This is an increase from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. This represents a yield of 1.2%. The ex-dividend date of this dividend is Monday, March 31st. Novo Nordisk A/S’s payout ratio is 47.72%.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.